SCHEMBL5035802

SCHEMBL5035802

Cc1cc(N2CCCC2)c2ccc(OS(C)(=O)=O)cc2n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 6/20 0.54
LMNA P02545 3/20 0.46
HTT P42858 3/20 0.46
USP2 O75604 2/20 0.46
MAPK1 P28482 2/20 0.46
PKM P14618 1/20 0.46
HSD17B10 Q99714 1/20 0.46
ADRB2 P07550 1/20 0.43
ADRB1 P08588 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
NPSR1 Q6W5P4 2/20 0.42
TSHR P16473 1/20 0.42
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
TUBB4A P04350 1/20 0.40
TUBB P07437 1/20 0.40
TUBA3C P0DPH7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5040541 0.87 NCF1 (0.51) NCF1LMNAHTTUSP2MAPK1
SCHEMBL5036263 0.83 NCF1 (0.61) NCF1ADRB2ADRB1NPSR1TSHR
Hydrochloric Acid SCHEMBL6377887 0.82 NCF1 (0.59) NCF1ADRB2ADRB1NPSR1TSHR
SCHEMBL5873086 0.82 NCF1 (0.63) NCF1ADRB2ADRB1NPSR1TSHR
SCHEMBL5040479 0.80 NCF1 (0.57) NCF1LMNAHTTUSP2MAPK1
SCHEMBL5033185 0.80 NCF1 (0.57) NCF1HTTHSD17B10ADRB2ADRB1
Hydrochloric Acid SCHEMBL5036055 0.79 NCF1 (0.56) NCF1LMNAHTTUSP2MAPK1
SCHEMBL5024607 0.78 MAPK1 (0.55) NCF1LMNAHTTUSP2MAPK1
SCHEMBL5037355 0.77 NCF1 (0.53) NCF1HTTMAPK1HSD17B10ADRB2
SCHEMBL5037445 0.77 NCF1 (0.53) NCF1HSD17B10ADRB2ADRB1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1395564-B1 QUINOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR HOFFMANN LA ROCHE (CH) 2008-02-27 EP disclosed
US-20050049413-A1 Quinoline derivatives MUELLER WERNER (CH) 2005-03-03 US disclosed
US-6818767-B2 NEUROPEPTIDE Y (NPY) ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF ARTHRITIS, CARDIOVASCULAR DISEASES, DIABETES, RENAL FAILURE, EATING DISORDERS, OR OBESITY HOFFMANN-LA ROCHE INC. 2004-11-16 US disclosed
EP-1395564-A1 QUINOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR F. HOFFMANN-LA ROCHE AG (CH) 2004-03-10 EP disclosed
US-20020198194-A1 Quinoline derivatives HOFFMANN-LA ROCHE INC. 2002-12-26 US disclosed
WO-2002094789-A1 QUINOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR F. HOFFMANN-LA ROCHE AG (CH) 2002-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198194-A1 Quinoline derivatives NPY2R, NPY1R, NPY4R NCF1 1052/4885LMNA 3209/4885HTT 224/4885
US-20050049413-A1 Quinoline derivatives NPY2R, NPY1R, NPY4R NCF1 1052/4885LMNA 3209/4885HTT 224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.